Latest Breaking News On - New york heart association - Page 1 : comparemela.com

Aficamten improves oxygen uptake in patients with obstructive hypertrophic cardiomyopathy

1. In this randomized controlled trial, aficamten significantly improved peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) compared with placebo. 2. The results for all 10 secondary endpoints were significantly improved with aficamten. Evidence Rating Level: 1 (Excellent) Study Rundown: HCM is one of the most common genetic heart diseases and is

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM

Treatment-Related Early Increase in Serum TTR is Associated With Lower Cardiovascular Mortality in ATTR-CM: Insights From ATTRibute-CM Amrut.

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy

Early Increase in Serum Transthyretin Level Is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM .

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients

Higher Risk of Mortality in Previously Hospitalized Patients: Insights From ATTRibute-CM Ahmad Masri1, Michele Emdin2, Keyur Shah3, Kunal Bhatt4,.

Heart Failure Patients Who Do Yoga Have Stronger Hearts and Can be More Active